Rafferty Asset Management, LLC - BIOXCEL THERAPEUTICS INC ownership

BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 85 filers reported holding BIOXCEL THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.0%.

Quarter-by-quarter ownership
Rafferty Asset Management, LLC ownership history of BIOXCEL THERAPEUTICS INC
ValueSharesWeighting
Q2 2023$1,316,242
-52.7%
197,634
+32.5%
0.01%
-63.2%
Q1 2023$2,782,430
+43.2%
149,112
+60.5%
0.02%
+58.3%
Q1 2022$1,943,000
-3.1%
92,928
-5.8%
0.01%
+9.1%
Q4 2021$2,005,000
+10.5%
98,638
+64.9%
0.01%
-8.3%
Q3 2021$1,815,000
-9.3%
59,803
-13.2%
0.01%
-7.7%
Q2 2021$2,002,000
-34.6%
68,900
-2.9%
0.01%
-38.1%
Q1 2021$3,061,000
+206.4%
70,924
+228.0%
0.02%
+110.0%
Q4 2020$999,000
-47.8%
21,624
-51.0%
0.01%
-56.5%
Q3 2020$1,914,000
+158.6%
44,152
+216.3%
0.02%
+130.0%
Q2 2020$740,00013,9600.01%
Other shareholders
BIOXCEL THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Logos Global Management LP 430,000$19,866,0001.70%
APIS CAPITAL ADVISORS, LLC 20,000$924,0000.89%
Avidity Partners Management LP 547,000$25,271,0000.82%
Knoll Capital Management, LLC 20,000$924,0000.63%
Artemis Investment Management LLP 1,013,448$46,839,0000.49%
AlphaCentric Advisors LLC 25,000$1,155,0000.48%
First Light Asset Management, LLC 94,202$4,352,0000.32%
Ikarian Capital, LLC 150,000$6,930,0000.31%
Longitude (Cayman) Ltd. 8,000$370,0000.18%
AllSquare Wealth Management LLC 5,490$254,0000.17%
View complete list of BIOXCEL THERAPEUTICS INC shareholders